HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study.

Abstract
A phase II study of dianhydrogalactitol in patients with advanced lung cancer yielded responses in three of 33 patients with adenocarcinoma and in one of 11 patients with large cell anaplastic carcinoma. Small cell and squamous cell carcinomas were unresponsive. Toxic effects were acceptable and were related to serum creatinine values.
AuthorsC D Haas, L Baker, T Thigpen
JournalCancer treatment reports (Cancer Treat Rep) 1981 Jan-Feb Vol. 65 Issue 1-2 Pg. 115-7 ISSN: 0361-5960 [Print] United States
PMID6261943 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Sugar Alcohols
  • Dianhydrogalactitol
Topics
  • Adenocarcinoma (drug therapy)
  • Carcinoma, Small Cell (drug therapy)
  • Carcinoma, Squamous Cell (drug therapy)
  • Dianhydrogalactitol (adverse effects, therapeutic use)
  • Drug Evaluation
  • Humans
  • Leukopenia (chemically induced)
  • Lung Neoplasms (drug therapy)
  • Sugar Alcohols (therapeutic use)
  • Thrombocytopenia (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: